Which catheter delivers better chemo to liver tumors? small trial aims to find out
NCT ID NCT06204159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see which catheter provides better coverage of the tumor with the chemotherapy agent Lipiodol, as seen on CT scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lipiodol (chemotherapy delivery agent) via TACE procedure
What this could lead to
If successful, this could help doctors choose the best catheter for delivering chemotherapy directly to liver tumors, potentially improving treatment effectiveness.
What could go wrong
This is a very small, early-stage study (12 participants) comparing two already-approved devices. It may not show a clear difference or lead to changes in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pennsylvania, Department of Radiology, Interventional Radiology Division
Philadelphia, Pennsylvania, 19104, United States